Common Diabetes Drug May Protect Against Vision Loss from Macular Degeneration

A widely prescribed medication for type 2 diabetes, metformin, may offer a new avenue for protecting vision in older adults at risk of age-related macular degeneration (AMD), a leading cause of blindness. Recent research suggests a significant link between metformin use and a reduced risk of developing the intermediate stage of this debilitating eye disease.

Understanding Age-Related Macular Degeneration

AMD affects the central portion of the retina, the macula, which is responsible for sharp, detailed vision. As AMD progresses, it damages the light-sensitive tissue in the macula. This damage can manifest in two primary forms:

• Dry AMD (Geographic Atrophy): Gradual deterioration of the macula.
• Wet AMD: Development of abnormal blood vessels that leak fluid and damage the retina.

AMD is a significant public health concern, affecting approximately 10 to 15 percent of people over the age of 65 [1]. It is the most common cause of blindness in high-income countries and carries a substantial economic burden, estimated at £11.1 billion annually in the UK alone [1].

Study Reveals Protective Link

A recent study conducted by researchers at the University of Liverpool analyzed retinal photographs of approximately 2,000 people with diabetes who participated in routine eye screenings over a five-year period [2], [3]. The analysis compared individuals taking metformin to those who were not.

The findings revealed that people with diabetes over 55 who were taking metformin had a 37% lower chance of developing intermediate AMD over the five-year period [3]. Specifically, the likelihood of developing intermediate AMD in people taking metformin was 0.63 compared with those not taking the medication (95% confidence range 0.43 to 0.92) [1].

How Metformin May Offer Protection

While the exact mechanisms are still under investigation, scientists have previously hypothesized that metformin may have protective effects against AMD [1]. This study is the first to directly evaluate AMD severity by grading retinal photographs, offering stronger evidence than previous research that relied on indirect indicators like diagnostic codes or insurance claims [1].

What This Means for the Future

Dr. Nick Beare, the lead researcher, emphasizes the potential impact of these findings: “Most people who suffer from AMD have no treatment, so this is a great breakthrough in our search for new treatments. What we need to do now is test metformin as a treatment for AMD in a clinical trial. Metformin has the potential to save many people’s sight.” [4]

While these results are promising, experts caution that metformin should not yet be prescribed specifically for treating AMD. Further research, including clinical trials, is necessary to confirm the association and determine the optimal dosage and long-term effects.